[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tamara C Tamas\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":4},"100592359","observational-study-of-intranasal-ivig-in-severe-acute-respiratory-syndrome-coronavirus-2-sars-cov-2-patients-undergoing-medical-tourism-100592359",false,"NCT06992401","Observational Study of Intranasal IVIG in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients Undergoing Medical Tourism","An Observational Study Collecting Real-World Data on Intranasal IVIG Treatment in Long COVID-19 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients With Immunodeficiency Engaged in International Medical Tourism","IVIG-LC","Inclusion Criteria:\n\n* Age 18 to 65 years\n* Clinical diagnosis of Long COVID (symptoms persisting ≥12 weeks after SARS-CoV-2 infection)\n* Laboratory-confirmed immunodeficiency, including one or more of the following:\n* Low serum IgG and\u002For IgA\n* Specific antibody deficiency\n* Low pneumonia titers\n* Elevated inflammatory markers (e.g., CRP, cytokines)\n* No active infections at the time of enrollment (bacterial, viral, or fungal)\n* Negative for Lyme disease and NMDAR antibodies\n* Willingness to provide informed consent for data collection and use\n\nExclusion Criteria:\n\n* Current or recent active infection (e.g., viral, bacterial, or fungal)\n* Use of immunosuppressive therapy within the last 3 months\n* Active infections: Participants with active infections, including viral, bacterial, or fungal infections, will be excluded\n* Neurological disorders: Participants with diagnosed neurological disorders (e.g., multiple sclerosis, Parkinson's disease, Alzheimer's disease) will be excluded\n* Immunosuppressive therapy: Participants receiving immunosuppressive therapy will be excluded\n* Inability to comply with study assessments or procedures","ALL","18 Years","65 Years",{"count":21,"type":22},50,"ESTIMATED","12 Weeks","OBSERVATIONAL","This observational study is being conducted by Healing Hope International to collect real-world data on an emerging treatment approach for Long COVID in patients with immunodeficiency. The study investigates the effects of intranasal immunoglobulin (IVIG) therapy in a real-world setting.\n\nParticipants will be individuals diagnosed with Long COVID who have confirmed immunodeficiency, such as low IgG or IgA levels or specific antibody deficiency. These individuals are receiving care through international clinical programs and will not receive any treatment as part of this study. Instead, Healing Hope will collect health information, clinical outcomes, and laboratory results from participating sites to better understand how intranasal IVIG might help reduce symptoms such as fatigue, brain fog, inflammation, and immune dysregulation.\n\nThe goal of this study is to contribute new insights into potential treatment options for Long COVID and to support responsible, science-backed care models for patients participating in medical tourism. No experimental drugs are being administered as part of this protocol. All treatment decisions are made independently by each clinical site. Data will be anonymized and used to advance knowledge in the field of immunological recovery and neuroinflammation.",[27,28,29,30,31,32],"Post-Acute Sequelae of SARS-CoV-2 Infection","Long COVID","Long COVID Fatigue","Long COVID Syndrome","COVID 19 Associated Coagulopathy","COVID-19 Vaccination",[34,35,36,37,38,39,40,41,42,43,44,45],"Intranasal IVIG","Real-world data","Medical tourism","Long COVID fatigue","Cytokine panel","Immunoglobulin therapy","Brain fog","Chronic inflammation","Real-world evidence","Global health","Post-viral syndrome","Immune recovery","NOT_YET_RECRUITING","2025-11-24",{"date":49,"type":50},"2025-12-02","ACTUAL",{"date":52,"type":22},"2026-08-01",{"date":54,"type":22},"2029-07-15",{"name":56,"class":57},"Tamara C Tamas","OTHER",""]